我要投票 三九药房在保健药品行业中的票数:141
· 外 推 电 报 ·
2025-03-29 08:22:29 星期六

【三九药房是哪个国家的品牌?】

三九药房是什么牌子?「三九药房」是 杭州三九医药连锁有限公司 旗下著名品牌。该品牌发源于浙江,由创始人李斌在2002期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力三九药房品牌出海!通过在本页面挂载三九药房品牌的产品链接和联系邮箱,可以提高三九药房产品曝光!跨境电商爆单神器,目前只要100元/年哦~

三九医药股份有限公司(以下简称“本公司”)是一家在中华人民共和国注册的股份有限公司,于1999年3月2日经原国家经济贸易管理委员会国经贸企改[1999]134号文件批准,由深圳三九药业有限公司(以下简称“三九药业”)、三九企业集团(深圳南方制药厂)(以下简称“三九集团”)、深圳九先生物工程有限公司(以下简称“九先生物 ”)、深圳市先达明物业管理有限公司(以下简称“先达明物业”)和惠州市壬星工贸有限公司共同发起设立,并于1999年4月21日经国家工商行政管理总局核准登记。

于2008年5月22日,经广东省深圳市工商行政管理局核准登记,本公司换领注册号为440301103302647的企业法人营业执照。本公司所发行人民币普通股A 股股票,已在深圳证券交易所上市。

本公司注册成立时原注册资本为人民币55,300万元,股本总数55,300万股。

本公司经中国证券监督管理委员会以证监发行字[1999]142号文批准,于1999年11三九医药股份有限公司月面向社会公众发行人民币普通股20,000万股。

于2000年3月9日在深圳证券交易所正式上市交易,注册资本增加为75,300万元,股本总数75,300万股,其中国有发起人持有55,200万股,境内法人持有100万股,社会公众持有20,000万股。本公司股票面值为每股人民币1元。

根据本公司2003年度第二次股东大会决议,本公司以2002年12月31日股本75,300万股为基数,按每10股由资本公积转增3股,共计转增22,590万股(每股面值1元),并于20 03年度实施。转增后,本公司注册资本增至人民币97,890万元,但增资的工商变更手续尚未办理完毕。

截至2008年12月31日,本公司累计发行股本总数97,890万股。

于2008 年4 月16 日,根据国资委国资产权[2008]384 号文《关于三九医药股份有限公司国有股东股权变更有关问题的批复》,三九集团所持有的本公司84,462,5 20 股国有法人股股份及三九药业所持有的本公司613,937,480 股国有法人股股份的持股主体统一变更为新三九控股有限公司(以下简称“新三九控股”)。

于2008 年6 月16 日,商务部以商资批[2008]602 号文《商务部关于同意三九医药股份有限公司股权转让的批复》同意了上述股权变更。

截至2008 年12 月31 日,除三九集团所持有的42,019, 587 股股份尚未完成变更审批及过户程序外,其余涉及转让股份已全部在中国证券登记结算有限责任公司深圳分公司办理过户登记确认书并过户至新三九控股。公司于2007年11月底正式进入华润集团。

2010年2月,经国家工商行政管理总局审核,并经深圳市市场监督管理局核准,公司名称由“三九医药股份有限公司”正式变更为"华润三九医药股份有限公司"。


英文翻译:Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "the company") is a joint stock limited company registered in the people's Republic of China, approved by the former State Economic and Trade Administration Commission, State Economic and trade enterprise reform [1999] No. 134 document on March 2, 1999. It is approved by Shenzhen Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "Sanjiu pharmaceutical"), Sanjiu enterprise group (Shenzhen Nanfang pharmaceutical factory) (hereinafter referred to as "Sanjiu pharmaceutical") Jiuxian group), Shenzhen Jiuxian Bioengineering Co., Ltd. (hereinafter referred to as "Jiuxian biology"), Shenzhen xiandaming Property Management Co., Ltd. (hereinafter referred to as "xiandaming property") and Huizhou Renxing industry and Trade Co., Ltd. jointly initiated the establishment, which was approved and registered by the State Administration for Industry and Commerce on April 21, 1999. On May 22, 2008, upon the approval and registration of Shenzhen Administration for Industry and Commerce of Guangdong Province, the company renewed the business license of enterprise legal person with the registration number of 440301103302647. A shares of RMB common stock issued by the company have been listed on Shenzhen Stock Exchange. The original registered capital of the company at the time of its incorporation was 553 million yuan, with a total share capital of 553 million shares. Approved by China Securities Regulatory Commission with zjxz [1999] No. 142 document, the company issued 200 million RMB ordinary shares to the public on November 9, 1999. It was officially listed and traded on Shenzhen Stock Exchange on March 9, 2000. The registered capital was increased to 753 million yuan, with a total share capital of 753 million shares. Its Chinese sponsors hold 552 million shares, domestic legal persons hold 1 million shares, and the public holds 200 million shares. The par value of the company's shares is 1 yuan per share. According to the resolution of the second general meeting of shareholders of the company in 2003, based on the capital stock of 753 million shares as of December 31, 2002, the company increased 3 shares from capital reserve for every 10 shares, with a total of 225.9 million shares (par value of 1 yuan per share) transferred and implemented in 2003. After the increase, the registered capital of the company increased to RMB 978.9 million, but the industrial and commercial procedures for the change of capital increase have not been completed. As of December 31, 2008, the company has issued a total of 978.9 million shares. On April 16, 2008, according to the reply to the relevant issues on the change of state-owned shareholders' equity of Sanjiu Pharmaceutical Co., Ltd. issued by SASAC GZQ [2008] No. 384, 84462520 shares of state-owned legal person held by Sanjiu group and 613937 shares of the company held by Sanjiu Pharmaceutical Co., Ltd, The shareholding subject of 480 shares of state-owned legal person shares is changed into new Sanjiu Holding Co., Ltd. (hereinafter referred to as "new Sanjiu holding"). On June 16, 2008, the Ministry of Commerce approved the above equity change with the document of SZP [2008] No. 602 Reply of the Ministry of Commerce on Approving the equity transfer of Sanjiu Pharmaceutical Co., Ltd. As of December 31, 2008, except that 42019587 shares held by Sanjiu group have not yet completed the change approval and transfer procedures, all other shares involved in the transfer have been registered in Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. and transferred to new Sanjiu holdings. The company officially entered China Resources Group at the end of November 2007. In February 2010, the company's name was officially changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd." after being reviewed by the State Administration for Industry and Commerce and approved by Shenzhen market supervision and Administration Bureau.

本文链接: https://www.waitui.com/brand/262c2aa7a.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

融创中国:2024年收入约为740.2亿元,同比减少约52%

36氪获悉,融创中国公告,2024年收入约为740.2亿元,同比减少约52%;公司拥有人应占亏损约为257亿元,上年同期公司拥有人应占亏损约为79.7亿元。

23分钟前

国泰君安:2024年净利润同比增长38.94%,拟每10股派2.8元

36氪获悉,国泰君安公告,2024年实现营业收入433.97亿元,同比增长20.08%;归母净利润130.24亿元,同比增长38.94%。公司拟每10股派发现金红利2.8元(含税)。

23分钟前

美股大型科技股盘前多数下跌,亚马逊跌超1%

36氪获悉,美股大型科技股盘前多数下跌,截至发稿,亚马逊跌超1%,苹果跌0.89%,微软跌0.72%,谷歌跌0.62%,Meta跌0.59%,奈飞跌0.26%,特斯拉涨超1%,英伟达涨0.02%。

23分钟前

热门中概股美股盘前普跌,多股跌超2%

36氪获悉,热门中概股美股盘前普跌,截至发稿,京东、百度、哔哩哔哩、小鹏汽车、蔚来跌超2%,阿里巴巴、拼多多、理想汽车跌超1%。

23分钟前

苏宁易购:2024年盈利6.1亿元,同比增114.93%

36氪获悉,苏宁易购发布2024年度报告,公司全年实现归属于上市公司股东的净利润6.1亿元,同比增长114.93%,经营活动产生的现金流量净额45.86亿元,同比增长57.56%,自2020年以来首次实现全年盈利。其中,四季度门店销售规模同比增长64.6%,零售服务商战略深化显效。

23分钟前

本页详细列出关于兴卫医药的品牌信息,含品牌所属公司介绍,兴卫医药所处行业的品牌地位及优势。
咨询